HHS Awards $3.8M for Anthrax Vaccine Research to RHO Federal Systems Division Inc

Contract Overview

Contract Amount: $3,834,161 ($3.8M)

Contractor: RHO Federal Systems Division Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2022-09-19

End Date: 2027-09-18

Contract Duration: 1,825 days

Daily Burn Rate: $2.1K/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: ANTHRAX AV7909 BOOST EVALUATION AND ANTIGEN-SPARING TRIAL (ABEAST)

Place of Performance

Location: DURHAM, DURHAM County, NORTH CAROLINA, 27713

State: North Carolina Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $3.8 million to RHO FEDERAL SYSTEMS DIVISION INC for work described as: ANTHRAX AV7909 BOOST EVALUATION AND ANTIGEN-SPARING TRIAL (ABEAST) Key points: 1. Contract focuses on advanced anthrax vaccine evaluation and antigen-sparing trials. 2. RHO Federal Systems Division Inc. is the sole awardee for this specific delivery order. 3. The contract duration is 5 years, indicating a long-term research objective. 4. Research and Development in Physical, Engineering, and Life Sciences is the relevant NAICS code.

Value Assessment

Rating: fair

The contract type is Cost Plus Fixed Fee, which can lead to cost overruns if not managed carefully. Benchmarking against similar R&D contracts is difficult without more detailed cost breakdowns.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, suggesting a competitive bidding process. However, this is a delivery order, and the initial award mechanism for the larger contract is not specified.

Taxpayer Impact: Taxpayer funds are being invested in critical biodefense research, aiming to improve vaccine efficacy and potentially reduce future healthcare burdens associated with anthrax.

Public Impact

Enhances national biodefense capabilities by advancing anthrax vaccine technology. Supports scientific research and development in a critical public health area. Potential for improved vaccine strategies that could be more cost-effective or efficient in the long run.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Positive Signals

Sector Analysis

This contract falls under Research and Development in the Physical, Engineering, and Life Sciences sector. Spending in this area is crucial for advancing scientific knowledge and developing new technologies, particularly in areas like biodefense.

Small Business Impact

The data indicates the awardee is RHO Federal Systems Division Inc., a large business. There is no specific indication of small business participation in this delivery order.

Oversight & Accountability

The contract is managed by the Department of Health and Human Services, Office of Assistant Secretary for Preparedness and Response, suggesting oversight within a relevant agency. Further details on specific oversight mechanisms are not provided.

Related Government Programs

Risk Flags

Tags

research-and-development-in-the-physical, department-of-health-and-human-services, nc, delivery-order, 1m-plus

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $3.8 million to RHO FEDERAL SYSTEMS DIVISION INC. ANTHRAX AV7909 BOOST EVALUATION AND ANTIGEN-SPARING TRIAL (ABEAST)

Who is the contractor on this award?

The obligated recipient is RHO FEDERAL SYSTEMS DIVISION INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $3.8 million.

What is the period of performance?

Start: 2022-09-19. End: 2027-09-18.

What is the specific scientific objective of the ABEAST trial and how does it aim to improve upon existing anthrax vaccine evaluations?

The ABEAST trial aims to evaluate the Anthrax AV7909 vaccine and explore antigen-sparing techniques. This could lead to more efficient vaccine production or the development of vaccines that require fewer doses or different components, potentially reducing costs and improving logistical challenges associated with large-scale vaccination campaigns.

What are the potential cost risks associated with a Cost Plus Fixed Fee contract for R&D, and how can they be mitigated?

Cost Plus Fixed Fee contracts can incentivize contractors to incur higher costs as their fee is fixed regardless of the total cost. Mitigation strategies include robust government oversight, clear performance metrics, detailed cost tracking, and well-defined scopes of work to prevent scope creep and ensure efficient resource utilization.

How does this research contribute to the broader effectiveness of the nation's biodefense strategy?

This research directly enhances the nation's biodefense by improving critical medical countermeasures against anthrax. More effective and potentially more economical vaccines strengthen our preparedness for bioterrorism events, ensuring a more robust response capability and protecting public health.

Industry Classification

NAICS: Professional, Scientific, and Technical ServicesScientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENTN – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Address: 2635 E NC HIGHWAY 54, DURHAM, NC, 27713

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Small Business, Special Designations, Subchapter S Corporation, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $3,882,538

Exercised Options: $3,834,161

Current Obligation: $3,834,161

Actual Outlays: $2,490,036

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Parent Contract

Parent Award PIID: 75A50120D00015

IDV Type: IDC

Timeline

Start Date: 2022-09-19

Current End Date: 2027-09-18

Potential End Date: 2027-09-18 00:00:00

Last Modified: 2026-03-30

More Contracts from RHO Federal Systems Division Inc

View all RHO Federal Systems Division Inc federal contracts →

Other Department of Health and Human Services Contracts

View all Department of Health and Human Services contracts →

Explore Related Government Spending